Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its management team will participate in the following virtual conferences in April.

• Needham Healthcare Conference 2022
  • Company Presentation by Chief Financial Officer Jeff Trigilio, Wednesday, April 13, 2022, 8:00 a.m. EDT

• Canaccord Genuity Horizons in Oncology Virtual Conference
  • Fireside Chat with Chief Executive Officer Nadim Ahmed, Thursday, April 14, 2022, 2:00 p.m. EDT

Live webcasts of the Needham conference presentation and Canaccord Genuity conference fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events.

Management will also be participating in one-on-one investor meetings. Investors interested in scheduling a meeting with Cullinan’s management should contact their respective financial institution representatives.

About Cullinan Oncology
Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.

Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.

Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com